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Key Points
Question
Do second primary malignant neoplasms (SPMs) have a similar detrimental impact on survival for children,
adolescents and young adults (AYAs), and older adults?
Findings
1 2 1 1 3
1
2
3
JAMA Oncology
In this cohort study, the impact of SPMs on survival was more pronounced in children and AYAs than older adults.
Adolescents and young adults with a second Hodgkin lymphoma, sarcoma, or breast, thyroid, or testicular cancers
had a greater than 2-fold increased risk of cancer-specific death than those with the same primary malignant
neoplasms, but no prior cancer.
Meaning
The adverse impact of SPMs on survival is substantial for AYAs and may partially explain the relative lack of
survival improvement in AYAs compared with older adults with the same cancers.
Abstract
Importance
Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after
cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary
malignant neoplasm (PM) by age.
Objective
To assess the survival impact of SPMs in adolescents and young adults (AYAs) (15-39 years) compared with that of
pediatric (<15 years) and older adult (≥40 years) patients with the same SPMs.
Design, Setting, and Participants
This was a population-based, retrospective cohort study of patients with cancer in 13 Surveillance, Epidemiology and
End Results regions in the United States diagnosed from 1992 to 2008 and followed through 2013. Data analysis was
performed between June 2016 and January 2017.
Main Outcomes and Measures
Five-year relative survival was calculated overall and for each cancer occurring as a PM or SPM by age at diagnosis.
The impact of SPM status on cancer-specific death was examined using multivariable Cox proportional hazards
regression.
Results
A total of 15 954 pediatric, 125 750 AYAs, and 878 370 older adult patients diagnosed as having 14 cancers occurring
as a PM or SPM were included. Overall, 5-year survival after an SPM was 33.1% lower for children, 20.2% lower for
AYAs, and 8.3% lower for older adults compared with a PM at the same age. For the most common SPMs in AYAs,
the absolute difference in 5-year survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary
breast carcinoma, 15% for secondary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma. Survival by
SPM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin
lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer. Adolescents and young
adults with secondary Hodgkin lymphoma (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]);
breast carcinoma (2.1 [1.8-2.4]); acute myeloid leukemia (1.9 [1.5-2.4]); and central nervous system cancer (1.8 [1.2-
2.8]) experienced worse survival compared with AYAs with the same PMs.
Conclusion and Relevance
The adverse impact of SPMs on survival is substantial for AYAs and may partially explain the relative lack of
survival improvement in AYAs compared with other age groups. The impact of a particular SPM diagnosis on
survival may inform age-specific prevention, screening, treatment, and survivorship recommendations.
Introduction
The increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer.
Although pediatric cancer survivors are at a higher risk of developing an SPM compared with older cancer survivors,
adolescent and young adult survivors (AYAs) have the highest absolute excess risk of SPMs among all age groups.
Studies have reported the increased late mortality after specific SPMs among young cancer survivors, but to our
knowledge, no study has assessed the survival impact of various SPMs in AYAs compared with pediatric and older
adult patients. It is possible that the detrimental effect of SPMs on survival accounts for some of the lack of survival
improvement in AYAs compared with pediatric and older adult patients with cancer. Therefore, using data from the
National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, we compared survival of
patients with SPMs with their corresponding first primary cancer types and determined if there were age-specific
differences in survival after SPMs.
Methods
Patients
All patients diagnosed with an invasive first primary malignant neoplasm (PM) or SPM (with known type of PM)
during 1992 to 2008 were identified from 13 SEER registries. Only 14 common AYA cancers (female breast cancer;
thyroid, melanoma, and testicular cancers; Hodgkin lymphoma; non-Hodgkin lymphoma; acute lymphoid leukemia;
acute myeloid leukemia; soft-tissue sarcoma; bone sarcoma; and colorectal, central nervous system, cervical, and
ovarian cancers) were included in this study.
From SEER, we obtained clinical and demographic information, including race/ethnicity, routinely recorded in the
medical record at diagnosis, and vital status, which for the deceased included underlying cause of death. Patients were
divided into 3 age groups by the age of diagnosis of the PM or SPM: children (<15 years), AYAs (15-39 years), and
older adults (≥40 years). The PM group patients had a PM only, and the PM and SPM did not necessarily occur in the
same age group.
Second primary malignant neoplasms diagnosed within 2 months of the PM were excluded to remove what were
likely multiple primary tumors. Second primary malignant neoplasms with histologic characteristics similar to those
of their corresponding PM were reviewed to verify that no SPMs would be considered recurrences according to the
updated SEER multiple primary coding rules or best clinical practice. Patients with invalid survival time (n = 7585)
were excluded. This study was approved by the University of California, Davis, institutional review board.
Statistical Analysis
Five-year relative survival and standard errors using the Ederer II method were calculated using SAS statistical
software (version 9.3; SAS institute Inc) with National Center for Health Statistics expected survival life tables.
Multivariable Cox proportional hazards regression at P < .05 was used to evaluate associations of SPM with survival,
controlling for age, race/ethnicity, sex, year of diagnosis, and stage at diagnosis (where applicable). For deceased
patients, survival time was measured from diagnosis date of the PM or SPM to the date of death from any cause (all-
cause death) and any cancer (cancer-specific death). Deaths from non–cancer-related causes were considered as
competing risks in analyses of cancer death. Patients alive at the study end date (December 31, 2013) were censored
at this date or at last known contact.
Results
A total of 15 954 pediatric, 125 750 AYA, and 878 370 older adult patients diagnosed as having 14 cancers occurring
as a PM or SPM were included in the study. Children with cancer were predominantly male, whereas AYA and older
adult patients were predominantly female (eTable 1 in the Supplement). The distribution of PMs and SPMs for each
age group are presented in eTable 1 in the Supplement, and the 3 most common PMs for those with an SPM are
presented in eTable 2 in the Supplement.
The 5-year relative survival for all selected cancers seems lower for those with SPMs than those with a PM, with the
largest absolute difference in 5-year survival observed for children (33.1%) and AYAs (20.2%) compared with older
adults (8.3%) (eTable 3 in the Supplement). In AYAs, 5-year relative survival for both a PM and SPM melanoma and
testicular cancer was high. However, 5-year relative survival seems lower for all other SPMs compared with
corresponding PMs in AYAs. For the most common SPMs in AYAs, the absolute differences in 5-year relative
survival were 41.9%, 18.9%, 15.0%, and 12.6% lower for non-Hodgkin lymphoma, breast cancer, thyroid cancer, and
soft-tissue sarcoma, respectively, than if these cancers occurred as a PM.
In multivariable-adjusted models, children with acute lymphoid leukemia, acute myeloid leukemia, and central
nervous system cancer as an SPM were at a higher risk of cancer death than that of the same PM (Table). In AYAs,
almost every SPM conferred a higher risk of death compared with the same PM. Secondary Hodgkin lymphoma and
thyroid cancer had more than a 3-fold increased risk, and secondary breast cancer, testicular cancer, soft-tissue
sarcoma, and bone sarcoma had more than a 2-fold increased risk of cancer-specific death. In general, SPMs in older
adults were associated with higher mortality, but the magnitude of associations was less than in AYAs. All-cause and
cancer-specific death by SPM status was significantly worse in younger patients for thyroid, Hodgkin lymphoma,
acute lymphoid leukemia, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer; all-cause
death by SPM status was significantly worse among younger patients for breast cancer, non-Hodgkin lymphoma,
colorectal cancer, and cervical cancer.
Discussion
In this large, population-based study, the impact of an SPM on survival for the 14 cancers considered was most
pronounced in AYAs and the relatively few SPMs that occurred in childhood compared with older adults. For the
most common SPMs in AYAs, the absolute differences in 5-year survival were substantial.
To our knowledge, we are the first to report such large differences in 5-year survival after a second breast cancer or
thyroid cancer by age. Possible explanations include a difference in aggressiveness of a PM vs SPM, the increased
probability that younger patients harbor a genetic syndrome and different distributions of PM in younger patients. An
initial thyroid carcinoma may also be a result of overdiagnosis (and thus not be clinically important) or related to the
latency time from the PM to thyroid SPM. Testicular cancer; soft-tissue sarcoma; bone sarcoma; and central nervous
system, colorectal, and cervical cancers as SPMs likewise conferred an increased risk of death in AYAs, although
melanoma and ovarian cancer did not.
We are also the first to report a large difference in survival for PM and SPM Hodgkin lymphoma and non-Hodgkin
lymphoma, particularly among children and AYAs. Treatment for any PM may have affected potential treatment
options for a non-Hodgkin lymphoma SPM owing to cumulative toxic effects, thus having an impact on prognosis. In
addition, in AYAs, 76% of PMs before non-Hodgkin lymphoma were Kaposi sarcoma, suggesting that an underlying
diagnosis of HIV/AIDS is having an impact on the prognosis of second non-Hodgkin lymphoma. Compared with
lymphomas, secondary acute lymphoid leukemia and acute myeloid leukemia portend an extremely poor prognosis
across all age groups, which may be related to different biology, including cytogenetic or epigenetic features, that
result in a poor response to therapy for secondary leukemias. The primary strength of the current study is the large
number of patients from population-based registries, increasing the generalizability of our results.
Limitations
Study limitations include a lack of detailed treatment information, comorbidities, health behaviors, and genetic
information. Also, younger populations tend to be more mobile, which may underestimate the number of SPMs
identified and lead to conservative (negatively biased) estimates of cancer survival.
Conclusions
The adverse impact of SPMs on both relative survival and cancer death seems greater for AYAs and pediatric patients
compared with older patients with cancer. Our findings suggest that SPMs may partially account for the relative lack
of improvement in 5-year relative survival in AYAs. As more young patients with cancer continue to live for many
decades as survivors, the impact of a particular SPM diagnosis on survival may inform age-specific prevention,
screening, treatment, and survivorship recommendations.
Notes
Supplement.
eTable 1. Characteristics of patients diagnosed with selected primary malignant neoplasms (N= 950,954) and
second primary malignant neoplasms (N= 69,120), by age group at diagnosis, SEER, 1992-2008
eTable 2. Frequency (percentage) of top three prior cancers occurring in children, adolescents and young
adults (AYAs) and older adults by diagnosis, SEER, 1992-2008
eTable 3. 5-Year relative survival and standard error (SE) of selected first and second primary malignant
neoplasms by age group at diagnosis, SEER, 1992-2008
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Figures and Tables

Table.
Hazard Ratios (HRs) for the Increased Risk of All-Cause and Cancer  Death After a Second Primary
Malignant Neoplasm Compared With a Primary Malignant Neoplasm, by Age Group of Diagnosis,
SEER, 1992-2008
Cancer site or type Age at Diagnosis, HR (95% CI), y P Value
<15 15-39 ≥40 All-
Cause
Cancer
All-Cause Cancer-
Specific
All-Cause Cancer-
Specific
All-Cause Cancer-
Specific
Breast carcinoma NA NA 2.12 (1.86-
2.41)
2.05 (1.76-
2.39)
1.50 (1.47-
1.53)
2.06 (1.99-
2.12)
<.001 .35
Thyroid carcinoma NA NA 13.23 (9.06-
19.32)
31.62 (18.26-
54.74)
1.70 (1.57-
1.83)
2.42 (2.14-
2.73)
<.001 <.001
Melanoma NA NA 1.46 (1.05-
2.04)
1.46 (0.98-
2.17)
1.19 (1.15-
1.23)
1.68 (1.59-
1.77)
.13 .30
Testicular cancer NA NA 1.65 (0.91-
3.00)
2.65 (1.23-
5.71)
1.70 (1.24-
2.34)
3.12 (2.09-
4.66)
.99 .72
Hodgkin lymphoma NA NA 3.69 (2.21-
6.16)
3.50 (1.73-
7.07)
1.14 (1.01-
1.28)
1.30 (1.12-
1.52)
<.001 .01
Non-Hodgkin
lymphoma
3.15 (0.99-
10.01)
2.23 (0.44-
11.17)
2.97 (2.61-
3.39)
0.70 (0.51-
0.97)
1.02 (0.99-
1.05)
1.09 (1.05-
1.13)
<.001 .01
Acute lymphoid
leukemia
4.00 (1.49-
10.73)
4.51 (2.16-
9.41)
1.60 (1.00-
2.56)
1.90 (1.20-
3.01)
1.13 (0.96-
1.33)
1.10 (0.93-
1.30)
.02 <.001
Acute myeloid
leukemia
2.59 (1.70-
3.92)
2.96 (1.92-
4.57)
2.07 (1.66-
2.58)
1.91 (1.50-
2.44)
1.08 (1.02-
1.13)
1.08 (1.03-
1.14)
<.001 <.001
Soft-tissue sarcoma 1.63 (0.71-
3.74)
1.20 (0.39-
3.64)
2.06 (1.68-
2.52)
2.80 (2.03-
3.87)
1.16 (1.09-
1.22)
1.31 (1.21-
1.41)
<.001 .002
Bone sarcoma 1.85 (0.86-
3.96)
1.95 (0.92-
4.12)
1.97 (1.08-
3.59)
2.26 (1.12-
4.56)
1.34 (1.13-
1.60)
1.56 (1.26-
1.93)
.16 .38
Colorectal cancer NA NA 1.77 (1.39-
2.27)
1.74 (1.28-
2.35)
1.14 (1.12-
1.16)
1.34 (1.31-
1.37)
<.001 .10
Central nervous
system cancer
3.69 (2.12-
6.40)
3.26 (1.75-
6.07)
1.91 (1.40-
2.61)
1.83 (1.22-
2.75)
0.98 (0.93-
1.04)
1.09 (1.03-
1.16)
<.001 <.001
Cervical cancer NA NA 1.54 (1.03-
2.29)
1.52 (0.86-
2.70)
1.24 (1.19-
1.29)
1.62 (1.54-
1.72)
<.001 .93
Ovarian cancer NA NA 1.36 (0.89-
2.08)
1.41 (0.92-
2.14)
1.05 (1.00-
1.11)
1.08 (1.02-
1.14)
.12 .15
Abbreviations: HR, hazard ratio; NA, not applicable; SEER, Surveillance, Epidemiology, and End Results.
Cancer death refers to death from any type of cancer.
Adjusted for 5-year age range, sex, race/ethnicity, year of diagnosis, and stage at diagnosis.
P value for interaction of SPM status by age group for all-cause and cancer death. For cancers with all 3 age groups, all-cause
death different between children and adolescent and young adults (AYAs) for central nervous system cancer, between children and
older adults for non-Hodgkin lymphoma, acute lymphoid leukemia, acute myeloid leukemia and central nervous system cancer,
and between AYAs and older adults for non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma and central nervous
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system cancer; cancer death different between children and AYAs for acute lymphoid leukemia and acute myeloid leukemia,
between children and older adults for acute myeloid leukemia and central nervous system cancer, and between AYAs and older
adults for non-Hodgkin lymphoma, acute lymphoid leukemia, acute myeloid leukemia and soft-tissue sarcoma.
Cancer type based on the SEER AYA site recode.
Cancer type based on SEER site recode.
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